Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Daegu Catholic University Industry Academic Cooperation Foundation currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This workload is assigned to 1 distinct examiner working within 1 distinct art unit. This indicates a highly specific point of interaction with the patent office rather than a broad distribution across multiple departments.
MOSHER, ERIC PARKER is identified as the busiest examiner for this portfolio. This specific examiner is responsible for 1 busiest examiner pending office action, which represents the entirety of the foundation's current pending workload. Because the total number of pending actions is 1, this examiner manages all active cases for the organization.
The presence of only 1 distinct art unit and 1 distinct examiner reflects a narrow channel of examination. Practitioners managing this portfolio interact with a single point of contact at the office. This structure simplifies the tracking of examiner behavior and art unit trends, as the foundation's current Biotechnology & Pharmaceuticals activity does not span multiple examination groups.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSHER, ERIC PARKER | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18496519 | CONTRAST AGENT FOR DIAGNOSIS OF VASCULAR DISEASE CONTAINING GADOLINIUM-BASED COMPOUND AS ACTIVE INGREDIENT AND SYNTHESIS METHOD THEREFOR | MOSHER, ERIC PARKER | 29d overdue |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18496519 | CONTRAST AGENT FOR DIAGNOSIS OF VASCULAR DISEASE CONTAINING GADOLINIUM-BASED COMPOUND AS ACTIVE INGREDIENT AND SYNTHESIS METHOD THEREFOR | MOSHER, ERIC PARKER | 1612 | §103 | Final Rejection | 29d overdue | Pending | Oct 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial